Xueru Zhu1, Yiwei Wang1, Wenji Xue1, Ruifen Wang2, Lifeng Wang2, Mei-Ling Zhu1, Leizhen Zheng1. 1. a Department of Oncology, Xinhua Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China. 2. b Department of Pathology, Xinhua Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Abstract
OBJECTIVE: Angiogenesis is one of the key processes in the development of malignant tumors. The vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) signaling pathway regulates branching angiogenesis in cancer. In this study, we analyzed the associations of VEGF/VEGFR-2 proteins and VEGFR-2 genetic variations with the prognosis of gastric cancer (GC). METHOD: We collected the clinical information of patients with GC and extracted genomic DNA from paraffin-embedded tissues. Immunohistochemical methods were used to detect the expression of VEGF and VEGFR-2 in GC tissues. Four single nucleotide polymorphisms of VEGFR-2 were detected by the TaqMan assay. The Kaplan-Meier method and Cox regression model were applied to analyze the associations between clinicopathological characteristics, VEGFR-2 polymorphisms and GC prognosis. RESULTS: A total of 256 cases of GC were included in our study. VEGFR-2 (+) and VEGFR-2 (++/+++) protein expression levels were detected in 83 and 135 cases, respectively. High expression of the VEGFR-2 protein was associated with the poor prognosis of GC (log-rank test P = 0.026). No statistical significance was observed for the association between VEGF and the prognosis of GC. The VEGFR-2 rs1870377 A > T genetic polymorphism was discovered to be associated with the prognosis of GC (AA vs. AT, HR = 1.69, 95% CI = 1.06-2.68, P = 0.027). CONCLUSION: Our study suggested that the high expression of VEGFR-2, as well as the VEGFR-2 rs1870377 A > T genetic polymorphism, may be prognostic markers for GC.
OBJECTIVE: Angiogenesis is one of the key processes in the development of malignant tumors. The vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) signaling pathway regulates branching angiogenesis in cancer. In this study, we analyzed the associations of VEGF/VEGFR-2 proteins and VEGFR-2 genetic variations with the prognosis of gastric cancer (GC). METHOD: We collected the clinical information of patients with GC and extracted genomic DNA from paraffin-embedded tissues. Immunohistochemical methods were used to detect the expression of VEGF and VEGFR-2 in GC tissues. Four single nucleotide polymorphisms of VEGFR-2 were detected by the TaqMan assay. The Kaplan-Meier method and Cox regression model were applied to analyze the associations between clinicopathological characteristics, VEGFR-2 polymorphisms and GC prognosis. RESULTS: A total of 256 cases of GC were included in our study. VEGFR-2 (+) and VEGFR-2 (++/+++) protein expression levels were detected in 83 and 135 cases, respectively. High expression of the VEGFR-2 protein was associated with the poor prognosis of GC (log-rank test P = 0.026). No statistical significance was observed for the association between VEGF and the prognosis of GC. The VEGFR-2rs1870377 A > T genetic polymorphism was discovered to be associated with the prognosis of GC (AA vs. AT, HR = 1.69, 95% CI = 1.06-2.68, P = 0.027). CONCLUSION: Our study suggested that the high expression of VEGFR-2, as well as the VEGFR-2rs1870377 A > T genetic polymorphism, may be prognostic markers for GC.
Authors: Chi Hoon Maeng; Jun Ho Yi; Jeeyun Lee; Jung Yong Hong; Moon Ki Choi; Hyun Ae Jung; Joon Oh Park; Se Hoon Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim Journal: Anticancer Res Date: 2013-10 Impact factor: 2.480
Authors: J G Kim; S K Sohn; Y S Chae; Y Y Cho; H-I Bae; G Yan; J Y Park; M-H Lee; H Y Chung; W Yu Journal: Ann Oncol Date: 2007-04-10 Impact factor: 32.976
Authors: Niyaz Zaman; Serena Santhana Dass; Persephone DU Parcq; Suzanne Macmahon; Lewis Gallagher; Lisa Thompson; Jamshid S Khorashad; Clara LimbÄck-Stanic Journal: Cancer Genomics Proteomics Date: 2020 Nov-Dec Impact factor: 4.069